Drug intelligence / Profile preview

SUM-201

Development stage: Unknown
Lead developer: Sumaya Biotech
Modality: Small Molecules
Administration: Intravenous

Overview

SUM-201 (also known as SC83288) is a small molecule antimalarial being developed by Sumaya Biotech for the treatment of severe malaria. It possesses a novel mechanism of action targeting the parasite's DNA and tRNAAsp methyltransferase, PfDNMT2, which links the drug's action to impaired epigenetic regulation. Designed as a potential second-line treatment to address increasing resistance against current therapies like artemisinin, SUM-201 is characterized by rapid parasite killing and a favorable safety margin. It is intended for intravenous administration, specifically targeting the asexual blood stages of Plasmodium falciparum.

Targets

PfDNMT2 (Plasmodium falciparum DNMT2)

Beyond the preview

Go deeper on SUM-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUM-201.

Explore the full profile